RxElite Signs Supply and Marketing Agreement With Hi-Tech Pharmacal
Posted on: Tuesday, 15 July 2008, 12:01 CDT
RxElite has signed a 10 year development, supply and marketing agreement with Hi-Tech Pharmacal, a manufacturer and marketer of liquid generic products.
Under the terms of the agreement, RxElite will be responsible for the exclusive US supply of active pharmaceutical ingredient to be used in the manufacture of the generic ophthalmic product.
The active pharmaceutical ingredient will be manufactured by RxElite's wholly owned subsidiary, FineTech Pharmaceuticals, at their production facility in Nesher, Israel.
Hi-Tech Pharmacal will be responsible for the development of the finished dose formulation, regulatory filing, and manufacturing, as well as marketing the ophthalmic product. Upon commercialization, the parties will share net proceeds from the sale of the product.
Rick Schindewolf, senior vice president of business development at RxElite, said: "This partnership reflects RxElite's continued drive to realize value from our acquisition of FineTech and its rich product portfolio. We look forward to working closely with Hi-Tech Pharmacal on this project and future projects."
Source: Datamonitor
Related Articles
- Hi-Tech Pharmacal Reports Financial Results for the Third Fiscal Quarter Ended January 31, 2007
- Hi-Tech Pharmacal Reports First Fiscal Quarter Results, Announces the Authorization of an Additional $10 Million for the Company's Share Repurchase Program and Reiterates Sales Guidance
- Hi-Tech Pharmacal to Release First Quarter Earnings and Hold Conference Call on September 7, 2006
- Hi-Tech Pharmacal to Release Fourth Quarter Earnings and Hold Conference Call on July 12, 2006
- Shares of Amityville-Based Hi-Tech Pharmacal Co. Jump 14 Percent on Strong Earnings
- Hi-Tech Pharmacal Reports an 8% Sales Increase and a 44% EPS Increase for the Third Fiscal Quarter Ended January 31, 2006
- News Services Incorrectly Linked Hi-Tech Pharmacal Co., Inc. To Another Company
- Hi-Tech Pharmacal Added to the NASDAQ Biotechnology Index
- Hi-Tech Pharmacal Reports a 27% Sales Increase and a 60% EPS Increase for the Quarter Ended July 31, 2005
 |
 |
User Comments (0)
RSS Feeds